AbbVie Announces Phase 3 AFFIRM study successfully met its co-primary and ranked secondary endpoints, demonstrating that SKYRIZI® (risankizumab) delivered via subcutaneous (SC) induction is superior to placebo in inducing clinical remission and endoscopic response in adults with moderately to severely active Crohn’s disease (CD). These results are significant as they establish the efficacy of an SC-only induction pathway, potentially offering a more flexible administration option for patients compared to traditional intravenous (IV) induction.
Study Overview and Methodology
- Study Name: AFFIRM (NCT06063967)
- Design: Global, Phase 3, randomized, double-blind, placebo-controlled.
- Population: 289 adult patients with moderately to severely active Crohn’s disease.
- Patient Profile: 65% of the population was “treatment-refractory” (had failed at least one advanced therapy). 50% had failed two or more advanced therapies.
- Treatment Arms: Patients were randomized 2:1 to receive either risankizumab (SC) or a placebo.
- Primary Endpoints: 1. Clinical Remission: Defined by a Crohn’s Disease Activity Index (CDAI) score < 150. 2. Endoscopic Response: Defined as a >50% reduction in SES-CD from baseline.
Read More: AbbVie and Genmab Announce Positive Phase 3 Results for Epcoritamab in Relapsed/Refractory DLBCL
Key Efficacy Results (Week 12)
Risankizumab SC induction showed statistically significant superiority over placebo across all evaluated groups at the 12-week mark.
| Metric | Risankizumab SC | Placebo | P-Value |
| Clinical Remission (Overall) | 55% | 30% | < 0.0001 |
| Endoscopic Response (Overall) | 44% | 14% | < 0.0001 |
| Clinical Remission (Bio-Naïve) | 73.1% | 27.3% | Significant |
| Clinical Remission (Prior Bio-Failure) | 45.2% | 30.8% | Significant |
Eli Lilly olomorasib ESMO 2026 Data Show Durable First-Line Activity in KRAS G12C-Mutant NSCLC
Lilly olomorasib ESMO 2026 results show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer. The data cover olomorasib with pembrolizumab, with or without […]
Johnson & Johnson ESMO 2026: JNJ-6143 RIPTAC Debut, RYBREVANT FASPRO and ERLEADA Lead Solid Tumor Slate
Johnson & Johnson will present more than 25 solid tumor abstracts at ESMO 2026, led by the first JNJ-6143 RIPTAC readout in prostate cancer, new […]
Eli Lilly Sofe-M Plus Bevacizumab Delivers 79% Response Rate in Platinum-Sensitive Ovarian Cancer at ESMO 2026
Lilly Sofe-M, an investigational FRα-targeting antibody-drug conjugate, combined with bevacizumab produced a 79.3% confirmed objective response rate and 100% disease control in platinum-sensitive ovarian cancer […]
Clinical Significance & Market Impact
Innovation in Administration: Most current biologics for Crohn’s disease require an initial intravenous (IV) loading dose in a clinical setting. The AFFIRM study validates a subcutaneous-only induction regimen. This shift could:
- Increase patient convenience by allowing home-based or simplified administration.
- Reduce the burden on infusion centers.
- Provide a competitive edge for AbbVie in the immunology market against other IL-23 and TNF inhibitors.
Last Modified:
